MTR-601 / Motorpharma, Motric Bio - LARVOL DELTA

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals (clinicaltrials.gov) - P1 | N=89 | Completed | Sponsor: Motric Bio | Recruiting ➔ Completed | Trial completion date: May 2024 ➔ Oct 2024 | Trial primary completion date: Mar 2024 ➔ Oct 2024

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Cerebral Palsy • CNS Disorders • Dystonia • Genetic Disorders • Movement Disorders • Multiple Sclerosis • Muscle Spasticity • Musculoskeletal Diseases • Orthopedics

MTR-601-201: Study of the Oral Treatment MTR-601 in Cervical Dystonia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Motric Bio | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Dystonia • Movement Disorders

MTR-601-201: Study of the Oral Treatment MTR-601 in Cervical Dystonia (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Motric Bio

New P2 trial • CNS Disorders • Dystonia • Movement Disorders

[VIRTUAL] First-In-Class Anti-Spastic Drug Candidate (MPH-220) Efficiently Relaxes Spastic Muscles and Improves Motor Functions in Gait Disorder in Preclinical Studies (ISC 2021) - "Phase I clinical trials are scheduled for the beginning of 2021. Funded by the Hungarian National Research, Development and Innovation Office (NVKP 16-1-2016-0051 and PIACI-KFI-2019-00488)."

Preclinical • Cardiovascular • CNS Disorders • Movement Disorders • Muscle Spasticity • Vascular Neurology